122 related articles for article (PubMed ID: 34825867)
1. Study on the Relationship between Rivaroxaban and Factor Xa Activity in Blood Based on HPLC-MS/MS.
Liu H; Zhao Z; Wang Y; Liu L; Yang Y; An Z
Curr Drug Metab; 2021; 22(14):1132-1138. PubMed ID: 34825867
[TBL] [Abstract][Full Text] [Related]
2. Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).
Derogis PB; Sanches LR; de Aranda VF; Colombini MP; Mangueira CL; Katz M; Faulhaber AC; Mendes CE; Ferreira CE; França CN; Guerra JC
PLoS One; 2017; 12(2):e0171272. PubMed ID: 28170419
[TBL] [Abstract][Full Text] [Related]
3. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
[TBL] [Abstract][Full Text] [Related]
4. Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization.
Wiesen MHJ; Blaich C; Taubert M; Jennissen V; Streichert T; Pfister R; Michels G
Eur J Clin Pharmacol; 2018 May; 74(5):611-618. PubMed ID: 29376194
[TBL] [Abstract][Full Text] [Related]
5. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
Horinaka S; Sugawara R; Yonezawa Y; Ishimitsu T
Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
[TBL] [Abstract][Full Text] [Related]
7. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Correlation Between Coagulation Indices and Rivaroxaban Concentrations.
Wu T; Wu S; Li M; Zhang J
Ann Pharmacother; 2024 Jan; 58(1):28-36. PubMed ID: 37125735
[TBL] [Abstract][Full Text] [Related]
9. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
Miklič M; Mavri A; Vene N; Söderblom L; Božič-Mijovski M; Pohanka A; Antovic J; Malmström RE
Eur J Clin Pharmacol; 2019 Aug; 75(8):1069-1075. PubMed ID: 31139866
[TBL] [Abstract][Full Text] [Related]
10. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
[TBL] [Abstract][Full Text] [Related]
11. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
Yates SG; Smith S; Tharpe W; Shen YM; Sarode R
Transfus Apher Sci; 2016 Oct; 55(2):212-215. PubMed ID: 27377884
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study.
Zhang F; Chen X; Wu T; Huang N; Li L; Yuan D; Xiang J; Wang N; Chen W; Zhang J
Clin Pharmacokinet; 2022 Jun; 61(6):881-893. PubMed ID: 35316848
[TBL] [Abstract][Full Text] [Related]
13. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
[TBL] [Abstract][Full Text] [Related]
14. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
Goto E; Horinaka S; Ishimitsu T; Kato T
Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
[TBL] [Abstract][Full Text] [Related]
15. Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study.
Li Y; Du L; Tang X; Chen Y; Mei D
BMC Pharmacol Toxicol; 2020 May; 21(1):38. PubMed ID: 32466800
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Determination of Rivaroxaban and Enalapril in Rat Plasma by UPLC-MS/MS and Its Application to A Pharmacokinetic Interaction Study.
Zheng S; Luo SB; Mei YB; Guo J; Tong LJ; Zhang Q; Ye XY
Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):229-236. PubMed ID: 30151746
[TBL] [Abstract][Full Text] [Related]
17. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.
Liu Z; Xie Q; Zhang H; Mu G; Zhou S; Wang Z; Jiang J; Xiang Q; Cui Y
Am J Cardiovasc Drugs; 2021 Nov; 21(6):669-679. PubMed ID: 34142346
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
Neira V; Corbalán R; Pereira J; Panes O; Garayar B; Aizman A; Llevaneras S; Villarroel L
Rev Med Chil; 2016 Sep; 144(9):1103-1111. PubMed ID: 28060970
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of thromboelastometry and its correlation with the HPLC-MS/MS quantification test.
Aranda VF; Derogis PBM; Sanches LR; Mangueira CLP; Katz M; Faulhaber ACL; Mendes CEA; Ferreira CEDS; França CN; Guerra JCC
Braz J Med Biol Res; 2019 Apr; 52(4):e8006. PubMed ID: 30970082
[TBL] [Abstract][Full Text] [Related]
20. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
Mani H; Rohde G; Stratmann G; Hesse C; Herth N; Schwers S; Perzborn E; Lindhoff-Last E
Thromb Haemost; 2012 Jul; 108(1):191-8. PubMed ID: 22534775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]